Based on the use of the MAPK7 inhibitor XMD8-92, it has been shown that MAPK7-dependent inhibition of p53 contributes to tumor growth in a xenograft model [23] [24], though XMD8-92 could have another cellular target besides MAPK7 [25]. This evidence concerns the gene MAPK7 and neoplasm.